183 related articles for article (PubMed ID: 29143142)
1. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
3. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
4. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
Karbalaie Niya MH; Salman-Tabar S; Bokharaei-Salim F; Behmanesh M; Keyvani H
Microb Pathog; 2017 Apr; 105():166-170. PubMed ID: 28161357
[TBL] [Abstract][Full Text] [Related]
6. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
[TBL] [Abstract][Full Text] [Related]
7. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
Peres-da-Silva A; Brandão-Mello CE; Lampe E
Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
[TBL] [Abstract][Full Text] [Related]
9. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
10. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
[TBL] [Abstract][Full Text] [Related]
12. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
Hirotsu Y; Kanda T; Matsumura H; Moriyama M; Yokosuka O; Omata M
Hepatol Int; 2015 Jul; 9(3):424-30. PubMed ID: 25791176
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.
Li Z; Zhang Y; Liu Y; Shao X; Luo Q; Cai Q; Zhao Z
Medicine (Baltimore); 2017 May; 96(19):e6830. PubMed ID: 28489763
[TBL] [Abstract][Full Text] [Related]
15. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
Younas S; Sumrin A; Hussain N; Bilal M
J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
[TBL] [Abstract][Full Text] [Related]
16. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
[TBL] [Abstract][Full Text] [Related]
17. Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection.
Lieveld FI; Swaans N; Newsum AM; Ho CK; Schinkel J; Molenkamp R; van der Meer JT; Arends JE; Hoepelman AI; Wensing AM; Siersema PD; van Erpecum KJ; Boland GJ
Ann Hepatol; 2016; 15(5):696-704. PubMed ID: 27493108
[TBL] [Abstract][Full Text] [Related]
18. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
Noble CF; Malta F; Lisboa-Neto G; Gomes-Gouvêa MS; Leite AGB; de Castro VFD; Santana RAF; Carrilho FJ; Mendes-Correa MC; Pinho JRR
Arch Virol; 2017 Jan; 162(1):165-169. PubMed ID: 27704215
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
Hedskog C; Dvory-Sobol H; Gontcharova V; Martin R; Ouyang W; Han B; Gane EJ; Brainard D; Hyland RH; Miller MD; Mo H; Svarovskaia E
J Viral Hepat; 2015 Nov; 22(11):871-81. PubMed ID: 25784085
[TBL] [Abstract][Full Text] [Related]
20. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
